Therapeutic targeting of inflammasome signaling by blocking interleukin-1

Research output: Chapter in Book/Report/Conference proceedingChapter


The production of active interleukin-1 (IL-1) is a major outcome of inflammasome signaling causing local and systemic inflammation. IL-1-mediated inflammation contributes to the pathogenesis of many human diseases including autoinflammatory diseases, rheumatic diseases, and cancer. Several therapeutic strategies to block IL-1 using biologics have been developed including neutralizing antibodies, decoy receptors, and receptor antagonists. Three IL-1 blockers Anakinra, Rilonacept, and Canakinumab are currently approved for clinical use while several more are in development. This chapter will describe the mechanisms of action and application of biologic IL-1 blockers in human disease.
Original languageEnglish
Title of host publicationInflammasome biology
EditorsPablo Pelegrin
PublisherElsevier Academic Press
Number of pages21
ISBN (Electronic)9780323918022
Publication statusPublished - 2023


Dive into the research topics of 'Therapeutic targeting of inflammasome signaling by blocking interleukin-1'. Together they form a unique fingerprint.

Cite this